
Open Your Free Demat Account
Enjoy low brokerage on delivery trades
BAJAJ BROKING
Abbott has partnered with MSD Pharmaceuticals to distribute sitagliptin-based diabetes drugs in India, including Januvia, Janumet, and Janumet XR. India has 101 million diabetics and 136 million pre-diabetics, making this a major strategic deal in chronic disease management.
Abbott and MSD Pharmaceuticals have signed a distribution agreement focused on MSD’s oral anti-diabetic medicines in India. Under the new arrangement, Abbott will market and distribute sitagliptin, sitagliptin/metformin, and sitagliptin/metformin XR—sold under the brands Januvia, Janumet, and Janumet XR.
This partnership strengthens Abbott’s position in India’s growing diabetes care market, where access and affordability remain key concerns.
Also read: Siemens Energy Lists on NSE & BSE from June 19 After Demerger
Partnership focus: Distribution of oral diabetes drugs by MSD
Brands included: Januvia, Janumet, Janumet XR
Drug type: Sitagliptin-based DPP4 inhibitors
Treatment scope: Type 2 diabetes management
Diabetic population in India: 101 million
Pre-diabetic population: 136 million
Impact: Wider distribution and deeper market penetration
Potential influence: Positive long-term movement in Abbott share price
Also read: Dabur Enters Nutraceutical Market with Digital Wellness Brand ‘Siens’
Brand Name | Composition | Drug Class | Indication |
Januvia | Sitagliptin | DPP4i | Type 2 Diabetes |
Janumet | Sitagliptin + Metformin | DPP4i + Biguanide | Type 2 Diabetes |
Janumet XR | Sitagliptin + Metformin (ER) | Extended Release | Type 2 Diabetes |
The new agreement allows MSD to continue serving patients across India while leveraging Abbott’s in-country distribution strength. With Abbott’s diversified healthcare portfolio and national reach, the sitagliptin-based drug line will become more accessible to diabetic patients across urban and rural markets.
This move is timely, considering the scale of the diabetes epidemic in India. As non-communicable diseases account for a major burden on the healthcare system, the availability of trusted and widely prescribed medicines like sitagliptin may help address the growing demand for effective diabetes care solutions.
Following the announcement, market watchers may closely monitor the long-term potential of this partnership. While there was no immediate spike in Abbott share price, expanded product lines and deeper market integration could strengthen Abbott’s diabetes segment. As adoption increases, investor sentiment around the diabetes portfolio could influence future trends in Abbott share price.
Also read: ESAF Small Finance Bank to Offload Rs.735 Crore Bad Loan Pool to ARC
Source: Economic Times
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading